MYRIAD ONCOLOGY

Comprehensive testing solutions for personalized cancer treatment planning

Actionable germline and genomic insights, seamlessly delivered to you and your practice

Germline:

MyRisk®
Hereditary Cancer Test

Genomic:

Precise Tumor®
Molecular Profile Test

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

EndoPredict®
Breast Cancer Prognostic Test

FOLR1/FRα
Immunohistochemistry Test

Myriad genetics®

MYRIAD: PAIRED TESTING

Today's guidelines recommend both germline and genomic testing

National guidelines support the combined use of germline and genomic testing to improve your patients' outcomes, and **Myriad offers a trusted one-stop solution for your testing needs.** Our streamlined approach to delivering germline testing, tumor profiling, and companion diagnostic testing ensures you can quickly identify comprehensive treatment options for your patients.

Improve clinical outcomes with paired germline *and* genomic testing

Fact: Up to 10% of germline mutations are missed with tumor testing alone[1]

Consequence: Without germline testing, patients may be missed, and they may not be identified as eligible for appropriate treatment options

The potential for change: Paired testing can reveal cancer etiology and guide treatment decisions

Highlights from the latest guidelines for oncology treatment

- ASCO's expert panel emphasizes the need for genomic sequencing to guide treatment in patients with metastatic or advanced solid tumor cancers.[1]
- National guidelines recommend germline testing for patients diagnosed with ovarian, breast, pancreatic, colon, and certain prostate cancers.[2]
- **NEW ASCO guidelines suggest offering germline testing to patients when they qualify—regardless of tumor testing results.**[3]

Consolidated. Streamlined. Simplified.

Choosing Myriad guarantees you a trusted testing partner that ensures consistent, accurate results, **eliminating the need to manage results from multiple sources.** That's because Myriad:

- **Consolidates** germline and genomic results in one place with a treatment-focused summary sheet
- **Cross-checks** between germline and genomic results to safeguard accuracy
- **Designs** customizable workflow solutions that fit seamlessly into your practice to reduce staff burden

MYRIAD: KEY ONCOLOGY PRODUCTS

Far-reaching solutions for all your testing needs

MyRisk®
Hereditary Cancer Test

Turnaround: Up to 14 days

- Multi-gene panel analyzes genes related to 11 types of cancer to help you determine if your patient has a germline variant.
- Helps guide treatment options and provide information on monitoring for secondary primary cancer.

Precise Tumor®
Molecular Profile Test

Turnaround: Up to 14 days

- Pan-cancer test using next-generation sequencing to identify variants within tumors.
- Aids in therapy prioritization and determining clinical trial eligibility.
- *Optional IHC stain* to determine **PD-L1** expression and inform immuno-oncology treatments for patients with solid tumors.

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

Turnaround: Up to 14 days

- Comprehensive FDA-approved tumor test to determine HRD status for ovarian cancer patients.
- Indicates whether patients will benefit from PARP inhibitor therapy.

EndoPredict®
Breast Cancer Prognostic Test

Turnaround: ~7 days

- Provides individualized recurrence risk up to 15 years post-diagnosis.
- Helps in determining breast cancer treatment options.

FOLR1/FRα
Immunohistochemistry Test

Turnaround: ~7 days

- IHC stain determines folate receptor alpha (FRα) expression.
- Informs treatment for platinum-resistant ovarian cancer patients.

1,000+

scientific publications, including major clinical trials where researchers used Myriad products, which have led to improvements in oncology practices and patient outcomes

Germline and genomic testing with Myriad helps you answer the key questions:

1. **Is a targeted treatment more beneficial for my patient?**
2. **Will my patient benefit from chemotherapy or PARP inhibitor therapy?**
3. **Is my patient eligible for optimal therapy if platinum-resistant?**
4. **Can my patient benefit from immuno-oncology therapy or clinical trials?**

IHC=immunohistochemistry.

Impact medical management decisions with genetic insights

The **MyRisk Hereditary Cancer Test** is a market-leading multi-gene panel that identifies whether your patient has a germline variant that may require more rigorous medical management. It provides the actionable, accurate insights you need to determine the best treatment options.



Guidelines-driven, clinically actionable

Evaluates 48 genes to determine risk for 11 hereditary cancers and helps determine risks for a second primary cancer while providing guidance for family member testing.

Identifies up to 63% of variants other labs cannot definitively classify.[4]

Offers the industry's lowest Variant of Uncertain Significance (VUS) rates in *BRCA1/2*.[5]

Each patient result comes with personalized, guideline-based guidance through our novel MyRisk Management Tool

Low VUS rates matter

Improve patient outcomes with our industry-leading variant classification. Low VUS rates mean less work for you, more certainty for patients, and increased awareness of cancer risk with appropriate monitoring.

BRCA1 VUS rate **0.3%**

BRCA2 VUS rate **0.7%**

Lowest reported in the industry[5]

Accurate testing that goes beyond patients' initial test results

- The Myriad myVision Variant Classification program continually monitors variant data
- Our **Lifetime Classification Commitment** sends amended reports whenever a patient's MyRisk VUS result is reclassified as *clinically significant*

60,000 **reports amended over 10 years**[6]

A $100 million investment in variant classification

- Proprietary, state-of-the-art tools help us classify and reclassify variants that competitors cannot
- In one real-world example, Myriad reclassified 54% of *BRCA1/2* VUSs reported by another laboratory[7]

Identify targeted treatments and clinical trials for advanced solid tumors

Precise Tumor is a molecular tumor profile test covering key guidelines and clinical trials for multiple solid tumors. Using next-generation sequencing, it detects SNVs, INDELs, CNVs, splice variants, and fusions through targeted exome sequencing. It provides the necessary coverage for accurate selection of FDA-approved therapies along with recommended clinical trials.



Thoughtfully designed, patient-focused

Evaluates >500 genes by DNA and RNA sequencing.

Comprehensive panel larger than a number of competitors.

Includes DNA, RNA, and immuno-oncology biomarkers for more actionable findings.

Validated to 98.91% Analytical Sensitivity and >99.99% Analytical Specificity with targeted exome sequencing.

Key cancer biomarkers

Breast	Ovarian	Endometrial	Colon	Pancreatic	Prostate		Lung		Pan-cancer
AR	*BRAF*	*ERBB2*	*BRAF*	*ALK*	*ATM*	*MLH1*	*ATK1*	*KRAS*	*NTRK1*
BRCA1	*BRCA1*	*ESR1*	*ERBB2*	*BRAF*	*AR*	*MSH2*	*ALK*	*MAP2K1*	*NTRK2*
BRCA2	*BRCA2*	*MLH1*	*KRAS*	*BRCA1*	*BRCA1*	*MSH6*	*BRAF*	*MET*	*NTRK3*
ERBB2	*MLH1*	*MSH2*	*NRAS*	*BRCA2*	*BRCA2*	*PALB2*	*DDR2*	*NRAS*	*TMB*
ESR1	*MSH2*	*MSH6*	*MLH1*	*ERBB2*	*CDK12*	*PMS2*	*EGFR*	*PIK3CA*	
PD-L1	*MSH6*	*PMS2*	*MSH2*	*FGFR2*	*CHEK2*	*RAD51D*	*ERBB2*	*PTEN*	
PGR	*PMS2*	*POLE*	*MSH6*	*KRAS*	*FANCA*		*FGFR1*	*RET*	
PIK3CA		*TP53*	*PMS2*	*NRG1*			*FGFR2*	*TP53*	
PTEN				*PALB2*			*FGFR3*	*PD-L1*	
				RET					
				ROS1					

Key immuno-oncology biomarkers

MSI: Microsatellite Instability

TMB: Tumor Mutational Burden

PD-L1: Programmed Death-Ligand 1

End-to-end workflow solutions to fit your practice needs

Myriad provides customizable services and workflow solutions designed to streamline testing without added cost to the clinic or patient. Our comprehensive approach sets us apart, ensuring you have the support you need from test to treatment decision.

Patient identification

- Tools to determine who meets testing guidelines

Seamless Ordering

- Up to four tests with one order via portal, paper, virtual, or EMR

Clear Results

- Treatment-focused summary sheet with easy-to-follow top-level results

Patient Access

- Affordable testing with financial assistance options
- Complimentary mobile phlebotomy services and at-home saliva tests

Pathology Support

- Turnaround time for tumor testing is up to 14 days from receipt of tissue
- Tissue specialists ensure tissue is quickly processed
- Prompt return of unused tissue to the pathology lab

Education

- Flexible pre- and post-test patient sessions with certified genetic counselors
- Medical Science Liaison support for clinicians and staff to discuss results

Simple test ordering and results

1. Fill out the test request form (portal, paper, or EMR).
2. Submit a blood or saliva sample for germline tests.
3. Our tissue team will contact your pathology partner for genomic test samples.
4. Results delivered in up to 14 days, with each test result reported as available to your preferred location.
5. Easy-to-interpret summary sheet of all tests ordered for each patient.

> *Myriad's streamlined process consolidates everything into one portal, improving my team's efficiency when placing orders and receiving results. I get critical genetic and genomic information that directly impacts counseling and treatment, providing immense value for my patients."*
>
> — **John K. Chan**, MD, Gynecological Oncologist
> Sutter Health

Quickly review results with a treatment-focused summary sheet

Our comprehensive testing solutions are designed to provide you with consolidated, actionable results at a glance. Spend less time sifting through data and more time making informed treatment decisions.

Efficiently review consolidated results to fit your busy schedule

Quickly see critical information for treatment decisions

Easily discuss results with your patient or use Myriad's services for support

One-sheet summary of key findings*

MMM6416594

CONFIDENTIAL Summary Generated: May 9, 2023

Myriad genetics

Summary Sheet

HEALTHCARE PROVIDER(S)	INSTITUTION	PATIENT

GERMLINE STATUS — **NEGATIVE**

BRACAnalysis	Accession #: 04186575-BLD	Reported: May 9, 2023

For full details on Myriad germline test results, please see the test report(s). If germline testing was initiated by another provider, please contact Myriad or ordering provider for full test report(s).

IHC STAINS

FRA	Accession #: 03809171-BLD	Reported: May 5, 2023	POSITIVE
PD-L1	Accession #: 03809171-BLD	Reported: May 4, 2023	POSITIVE

For full details on test results, please see the test report(s).

MYRIAD HRD STATUS — **POSITIVE**

MyChoice CDx	Accession #: 03809171-BLD	Reported: May 5, 2023

For full details on Myriad MyChoice CDx test results, please see the test report(s).

TUMOR MOLECULAR PROFILING

Precise Tumor	Accession #: 03809171-BLD	Reported: May 4, 2023

This list of genes is not intended to be representative of all findings that are included on the Precise Tumor report. For a full list of finding and genes analyzed, please see the individual test report to verify this information.

POTENTIALLY SIGNIFICANT FINDINGS		
Tier IA	Tier IB	Tier IIC
BRCA2		*TP53*

BIOMARKER	LEVEL
TMB	Low
MSI	Stable

34 CLINICAL TRIAL(S)
For details on clinical trials, please see the report

This summary is for informational purposes only. It is not a test result, and it should not be used for medical management. Please review the associated test result(s) to verify this information and for medical management purposes. If an amended report is issued for an associated test result, this summary may not be updated. For information on clinical trial eligibility, please see the Precise Tumor report.

Summary of key findings for all tests ordered on one sheet

Report date included with test result status for each test ordered

Quickly find the status of biomarkers relevant to all solid tumor types

Know how many clinical trials may be available for your patient

See potentially significant findings first to identify the most relevant parts of each test

*Summary sheet includes information from both FDA-approved and non-FDA-approved tests and will be reflective of the specific tests ordered for each patient.

Advanced solutions help you deliver a full range of care

Myriad: Paired germline *and* genomic testing

Our wide variety of integrated tests supports simplified processes, improved result consistency, and guaranteed actionable insights that you need to make informed treatment decisions.

Continue the conversation with your Myriad representative

Fewer administrative burdens and thorough testing results make it easier to manage complex cases. Let Myriad help you streamline the workflow and enhance accuracy so you can focus on improving patient outcomes.

To get started,
scan the QR code
or contact us at:
Helpmed@myriad.com
800-469-7423

Discover the added benefits of partnering with a leader in oncology diagnostics:

Trusted lab
- Over 30 years of oncology experience
- 50,000 ordering clinicians and strong collaborations with key opinion leaders

Comprehensive testing solutions
- Supports every stage of a patient's cancer journey

Ease of use
- One-sheet summary of actionable information in one place
- Quick access to critical data for patient management

Quicker results
- Faster turnaround times than most labs for timely treatment decisions

Patient access and education
- Affordable testing with financial assistance
- Flexible pre- and post-test sessions with certified genetic counselors

References: 1. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *J. Clin. Oncol.* 2022;40(11):1231-1258. doi:10.1200/jco.21.02767. **2.** National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN® Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2024. ©National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed September 22, 2023. Available at: NCCN.org. **3.** Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. *J Clin Oncol*. Published online May 17, 2024. doi:https://doi.org/10.1200/jco.24.00662. **4.** Gradishar W, Johnson K, Brown K, Mundt E, Manley S. Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory. *The Oncologist*. 2017;22(7):797-803. doi:https://doi.org/10.1634/theoncologist.2016-0431. **5.** Mundt E, et al. Driving Down the Rate of Variants of Uncertain Significance as the Myriad myRisk® Multigene Panel Grows [White paper]. Myriad Genetics. Oct 2019. **6.** Mersch J, Brown N, Pirzadeh-Miller S, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. *JAMA*. 2018;320(12):1266-1274. doi:https://doi.org/10.1001/jama.2018.13152. **7.** Internal data on file at Myriad Genetics, Inc.

Myriad genetics®
Myriad Genetics, Inc.
322 North 2200 West
Salt Lake City, Utah 84116